Vilazodone for Menopausal Hot Flashes

Completed · Not applicable · Has a placebo group

Conditions studied: Hot Flushes

In brief

This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.

Key facts

Study ID
NCT01680900
Run by
University of Pennsylvania
People needed
36
Starts
2012-11-01
Expected to finish
2013-08-01
Last updated by the study team
2015-01-14

Who can join

Age: 45 and older, up to 60. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.